Group | Median age (range) | Women (%) | Men (%) | No of patients | No of specimens |
SSA– | 61 (23 to 90) | 968 (55.3) | 848 (44.7) | 1816 | 2077 |
SSA-LD | 66 (31 to 95) | 147 (57.2) | 110 (42.8) | 257 | 271 |
SSA-HD | 72 (50 to 87) | 31 (68.9) | 14 (31.1) | 45 | 47 |
SSA-CA | 76 (61 to 88) | 16 (76.2) | 5 (23.8) | 21 | 21 |
HP | 59 (9 to 104) | 30458 (47.5) | 33636 (52.5) | 64094 | 77891 |
TSA | 63 (23 to 92) | 355 (50.9) | 343 (49.1) | 698 | 711 |
TSAHD | 65 (53 to 78) | 8 (72.7) | 3 (27.3) | 11 | 11 |
TA | 62 (6 to 106) | 31841 (42.2) | 43648 (57.8) | 75489 | 105308 |
TVA/VA | 64 (17 to 99) | 2991 (45.2) | 3625 (54.8) | 6616 | 7554 |
TAHD | 66 (37 to 92) | 351 (41.0) | 506 (59.0) | 857 | 969 |
TVAHD/VAHD | 65 (25 to 94) | 478 (45.2) | 580 (54.8) | 1058 | 1144 |
ADENOCA | 67 (24 to 99) | 940 (44.3) | 1181 (55.7) | 2121 | 2190 |
MHAP | 63.5 (32 to 88) | 106 (44.5) | 132 (55.5) | 238 | 241 |
MHAPHD | 69 (51 to 80) | 1 (16.7) | 5 (88.3) | 6 | 7 |
ADENOCA, adenocarcinoma without evidence of precursor sessile serrated adenoma; HP, hyperplastic polyp; MHAP, mixed hyperplastic-adenomatous polyp; MHAPHD, mixed hyperplastic-adenomatous polyp with high-grade dysplasia; SSA–, sessile serrated adenoma without dysplasia; SSA-CA, adenocarcinoma arising in a sessile serrated adenoma; SSA-HD, sessile serrated adenoma with high-grade dysplasia; SSA-LD, sessile serrated adenoma with low-grade dysplasia; TA, tubular adenoma; TA-HD, tubular adenoma with high-grade dysplasia; TSA, traditional serrated adenoma; TSA-HD, traditional serrated adenoma with high-grade dysplasia; TVA/VA, tubulovillous and villous adenomas; TVA-HD/VA-HD, tubulovillous and villous adenomas with high-grade dysplasia.